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Abstract: Advances in molecular biology and bioinformatics have 
resulted in the identification of a number of potential biomarkers that 
could be relevant in the management of patients with non–small-cell 
lung cancer (NSCLC). Although there is an increasing amount of lit-
erature related to these biomarkers, major issues need to be resolved 
including validity and reproducibility of results. Additionally, in 
order to interpret the existing literature accurately, a clear distinc-
tion must be made between the prognostic and predictive value of 
biomarkers. The practical applicability of biomarker discovery for 
patients with lung cancer includes the identification of patients with 
early-stage NSCLC who are most likely to benefit from adjuvant 
therapy. Information gleaned from biomarkers has the potential to 
help in evaluating the role of targeted therapies including immuno-
therapy in the neoadjuvant and adjuvant setting. The role of gene 
signatures and the use of newer platforms such as RNA, methylation, 
and protein signatures is being explored in patients with early-stage 
NSCLC. This review focuses on the applications of biomarker dis-
covery in patients with early-stage NSCLC.
Key Words: Lung cancer, Biomarkers, Early-stage lung cancer, 
Predictive, Prognostic.
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Lung cancer is the leading cause of cancer-related mortal-ity in the United States and the worldwide. Non–small-
cell lung cancer (NSCLC) is the most common form of lung 
cancer. Early-stage NSCLC (ES-NSCLC; stages I and II) 
accounts for approximately 18% of the cases.1 Most of these 
patients are treated with curative intent and often require mul-
timodality therapy.2,3 Despite these aggressive measures, the 
survival associated with ES-NSCLC is less than optimal with 
a 5-year overall survival (OS) ranging from 50% for stage IA 
disease to 15% for stage IIIA NSCLC.4
ES-NSCLC has assumed particular significance in recent 
years for two main reasons. First, the incidence of ES-NSCLC 
is expected to rise due to the use of computed tomography 
screening of high-risk patients which has demonstrated a sur-
vival benefit.5 Second, the outcomes of ES-NSCLC may poten-
tially benefit from an improved understanding of the molecular 
and immunologic basis of NSCLC which has already led to 
improved outcomes in advanced NSCLC.
Several clinical trials have demonstrated improved sur-
vival with postoperative chemotherapy in selected patients 
who undergo complete surgical resection.6,7 Available evi-
dence supports the use of adjuvant chemotherapy for stage II 
and stage IIIA, but not for stage IA NSCLC.8
There are several shortfalls to the current approach of 
selecting patients for adjuvant therapy based on the surgical stage 
alone. Given the marginal benefits and potential toxicities associ-
ated with chemotherapy, perhaps the greatest challenge lies in the 
identification of patients at the greatest risk of recurrence. One 
approach to identifying high-risk patients focuses on the biology 
of ES-NSCLC in an effort to predict the risk of recurrence and 
the potential for response to treatment by using biomarkers.
A biomarker is a “characteristic that is objectively mea-
sured and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention.” A prognostic biomarker is a factor 
that is associated with an outcome that is independent of treat-
ment, whereas a predictive biomarker interacts with the treat-
ment to influence outcome.9 There is good clinical evidence 
for a limited number of biomarkers that are used in clinical 
practice. Examples include the use of hormone receptor status 
in breast cancer. These biomarkers are prognostic of improved 
survival independent of cancer treatment and also predict the 
benefit of hormonal therapy with drugs such as tamoxifen.10 
Despite a concerted effort, there is a lack of biomarkers with 
potential application in the management of ES-NSCLC.
The search for a prognostic and predictive biomarker has 
to take into consideration two key points: the strength of evidence 
to support its use and the depth of information provided by a 
biomarker that adds to what is already known about the disease 
based on the clinical parameters. Although a plethora of potential 
prognostic biomarkers have been proposed in the past couple of 
decades, very few have been validated. In this review, we have 
focused on a very small number of these biomarkers, including 
immune markers and molecular signatures relevant to ES-NSCLC 
because of the potential promise associated with them.
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PROGNOSTIC BIOMARKERS
P53
The tumor suppressor gene, p53 is frequently altered 
in NSCLC.11 Although it is a well-established poor prognos-
tic factor in many tumors,12,13 in ES-NSCLC its prognostic 
role is controversial. A subgroup analysis of CALGB 9633, a 
phase III trial that randomized patients with stage IB NSCLC 
to observation or adjuvant chemotherapy, showed that p53 
expression by immunohistochemistry (IHC) was detectable in 
47% of the tumors, and correlated with shorter disease-free 
survival (hazard ratio [HR], 1.95; p = 0.003) and OS (HR, 
2.30; p = 0.0005) in multivariate analyses.14 A meta-analysis 
of pooled patient data from 43 studies which included patients 
with ES-NSCLC who underwent potentially curative resection 
showed that p53 mutation or overexpression was an indicator 
of poor prognosis, especially in patients with adenocarcinoma 
(ADC). Compared with patients with no alterations, patients 
with ADC and p53 overexpression or mutations had a 21.8% 
(p = 0.0000039) and 48% (p = 0.000031) reduction in 5-year 
OS, respectively.15
KRAS
RAS belongs to the family of small guanosine triphos-
phatase  (GTPase) proteins. Rodenhuis et al. first reported an 
association between KRAS mutations and NSCLC. They stud-
ied 39 NSCLC samples for the presence of NRAS, KRAS, and 
HRAS mutations or amplifications and concluded that muta-
tional KRAS activation may be an important early event in 
the pathogenesis of ADC of the lung.16 They also showed that 
KRAS mutations were present in more than 30% of the ADCs 
and was more frequent in smokers.17 Studies in ES-NSCLC 
report that KRAS mutations, especially at codon 12, are asso-
ciated with worse progression-free survival (PFS) and OS.18,19 
Slebos et al.20 were the first to show that differences in PFS 
and OS in patients with ES-NSCLC with and without KRAS 
mutations were significant (p = 0.038 and p = 0.001). The 
prognostic significance of KRAS in NSCLC was evaluated 
in a combined analysis of eight studies with a total of 881 
patients. KRAS mutations were detected in 25% of the cases 
and involved codons 12, 13, and 61 of the KRAS gene. For the 
KRAS mutant group, the relative risk for mortality was 2.35 
(95% CI, 1.61–3.22), compared with patients with wild type 
KRAS. However, these studies were heterogeneous and there 
were no adjustments for other clinical variables.21 In recent 
studies, the relevance of different amino acid substitutions in 
KRAS has been analyzed. Preclinical and retrospective data 
point out the importance of specific KRAS mutations on the 
prognosis of NSCLC, such as G12C or G12v in contrast to 
other substitutions.22 Despite the data presented above, the 
prognostic significance of KRAS remains controversial. In an 
analysis involving 300 patients with ES-NSCLC with tumors 
harboring KRAS mutations enrolled in four adjuvant trials, 
the presence or absence of mutations in KRAS codon 12 did 
not confer a survival disadvantage in the observation arms of 
these trials.23
PROGNOSTIC AND PREDICTIVE BIOMARKERS
Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is a 
member of the tyrosine kinase cell surface receptor family. 
Mutations in the gene encoding this protein results in constitu-
tive activation and amplification of intracellular signals which 
lead to proliferation, invasion, and migration of the cancer 
cells.24 The overall implications of the presence of EGFR 
mutations or amplification in ES-NSLC are not well defined. 
Rusch et al.25 detected EGFR overexpression by IHC in 74 
(71%) of 96 ES-NSCLC tumor samples. However, there was 
no association with OS. In a separate study, 53 ES-NSCLC 
tumor samples (79% ADC) were analyzed for the presence 
of EGFR mutations in exon 19 and 21 by polymerase chain 
reaction (PCR), and 32% samples were found to be harbor 
mutations. Presence of an EGFR mutation was identified as a 
favorable prognostic factor, with 5-year OS of 92% for EGFR-
mutated versus 57% for EGFR wild-type tumors (p = 0.037).26 
The same group reported a retrospective analysis of 180 
patients with either KRAS codon 12 mutation or EGFR muta-
tion (exons 18–21). This study showed that the presence of an 
EGFR mutation was associated with longer OS (p = 0.048). 
However, there was no impact on PFS.27 Liu et al.28 exam-
ined 130 ES-ADC samples for EGFR mutations in exon 19 
and 21 by nested PCR, and detected mutations in 44.3% sam-
ples. Presence of an EGFR mutation did not have an impact 
on median PFS (36.6 months for EGFR-mutated versus 25.7 
months for EGFR wild-type tumors; p = 0.56). A large ret-
rospective study reported the outcome of 1118 patients with 
resected ES-NSCLC of whom 20% had an EGFR mutation. 
The presence of an EGFR mutation correlated with longer OS 
(HR, 0.51; p < 0.001). A subgroup analysis was conducted 
in from a different dataset of 286 resected ES-NSCLC ADCs 
harboring EGFR mutations to determine the effect of adju-
vant EGFR tyrosine kinase inhibitor (TKI) therapy. Among 
286 patients receiving adjuvant TKI Cox regression analysis 
demonstrated a significant improvement in PFS (HR, 0.43; 
p =0 .001), but no significant differences in OS.29
Although, as illustrated above multiple retrospective 
analyses demonstrate improved survival in patients with com-
pletely resected EGFR-mutated ES-NSCLC, definitive con-
clusions can only be drawn by conducting large prospective 
clinical trials in this patient population.
Her2
Her2, a receptor tyrosine kinase and a member of 
the EGFR family is overexpressed in 20% of the advanced 
NSCLC and mutated in less than 2%.30,31 In ES-NSCLC, stud-
ies suggest that overexpression of Her2 mRNA or protein is 
associated with an unfavorable prognosis.32,33 In a retrospec-
tive study, 239 tumor samples of patients with ES-NSCLC 
were evaluated for Her2 overexpression, which was defined 
as an IHC score of 2+/3+ (scoring based on staining inten-
sity and the number of cells stained). Her2 overexpression 
was detected in 18% of the tumors. The relapse rate for Her2-
positive versus Her2-negative tumors was 60% versus 33%, 
respectively (p = 0.03) in the absence of adjuvant treatment.34 
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A different definition of Her2 positivity by IHC was used 
by Xia et al. who considered Her2 overexpression as any 
positive staining. In a study involving only stage I and IIA 
NSCLC, 74% of ADCs, and 54% of the squamous cell carci-
noma (SCC) were found to overexpress Her2. The 5-year OS 
was 65% versus 86% in Her2-positive versus Her2-negative 
tumors respectively (p = 0.014).35 Despite differences in the 
criteria used to define Her2 overexpression, both studies 
attribute negative prognostic value to Her2 overexpression in 
ES-NSCLC. Although the presence of a Her2 mutation can 
predict for the response to Her2-directed therapy in the meta-
static disease setting, its predictive value remains unclear in 
ES-NSCLC.36
Excision Repair Cross-
Complementation Group 1
The excision repair cross-complementation group 1 
(ERCC1) protein plays a rate-limiting role in the nucleotide 
excision repair pathway that recognizes and removes cispl-
atin-induced DNA adducts.37 In ES-NSCLC, tumor ERCC1 
expression appears to have both prognostic and predictive 
value. In one of the first studies evaluating ERCC1, 51 resected 
samples of NSCLC were analyzed for ERCC1 RNA expres-
sion by PCR. Overexpression was associated with improved 
survival (HR, 0.337; p = 0.018), suggesting the value of 
ERCC1 expression as a prognostic biomarker.38 Subsequent 
studies focused on the role of this gene as a predictive marker, 
wherein low ERCC1 expression levels are predictive of the 
benefit from cisplatin-based adjuvant chemotherapy. ERCC1 
expression by IHC was studied in patients with stage I–III 
NSCLC enrolled in the International Adjuvant Lung Cancer 
Trial. Adjuvant chemotherapy prolonged survival among 
patients with ERCC1-negative tumors (HR, 0.65; p = 0.002), 
but not among patients with ERCC1-positive tumors (HR, 
1.14; p = 0.40). However, subjects with ERCC1-positive 
tumors had better survival than subjects with ERCC1-negative 
tumors in the observation arm (HR, 0.66; p = 0.009). This and 
other studies have demonstrated the prognostic and predictive 
value of ERCC1 in ES-NSCLC.39,40
Despite these interesting results, utilization of ERCC1 
as a predictive marker is limited by the lack of reproducibility 
of results with the antibodies used in the IHC assay. Friboulet 
et al. repeated ERCC1 IHC staining on the original testing set 
of 589 samples from the International Adjuvant Lung Cancer 
Trial, and attempted to unsuccessfully validate the results uti-
lizing 494 samples collected from two independent phase III 
trials, JBR10 and CALGB 9633. There was a lack of correla-
tion between the 16 different antibodies used, and an inabil-
ity of these antibodies to identify various ERCC1 isoform 
specificities.41
Ribonucleotide Reductase M1
Ribonucleotide reductase M1 (RRM1) is the regulatory 
protein subunit of ribonucleotide reductase and is involved 
in DNA repair, carcinogenesis, and cancer progression. The 
mechanistic relationship between RRM1 levels and sensi-
tivity of tumors cells to gemcitabine has been demonstrated 
in preclinical studies.42 In ES-NSCLC, several studies have 
suggested a prognostic role for RRM1. In a study of 126 
patients with ES-NSCLC RRM1 expression was evaluated 
by PCR analysis. This study demonstrated better median 
OS in patients with higher levels of RRM1 (52 months ver-
sus 24 months, p = 0.013).43 Similarly, RRM1 expression by 
automated quantitative protein analysis was studied in 187 
patients with stage I NSCLC. In this study, the median OS 
was 120 months versus 60.2 months in the group with high 
RRM1 expression compared with the low expression group 
(p = 0.01).40 To evaluate the predictive potential of RRM1 
expression in the context of treatment with gemcitabine, a 
phase II study was conducted in the ES-NSCLC population 
with the choice of adjuvant therapy determined by RRM1 
protein expression. Eighty-five patients with stage I NSCLC 
were enrolled and the treatment was customized based on 
the expression of ERCC1 and RRM1. Among patients with 
RRM1-expressing tumors, the PFS at 2 years was 83% in 
patients receiving gemcitabine compared with 71% in patients 
in the observation arm. No statistical tests were performed to 
evaluate the significance of these observations. Hence, further 
studies are needed to determine the predictive value of RRM1 
expression in ES-NSCLC.44
BRCA
The BRCA gene is a tumor suppressor involved in the 
homologous recombination repair pathway, a mechanism for 
DNA repair. Methylation or mutations which decrease BRCA 
expression or activity have been shown to cause impairment 
in the homologous recombination repair pathway. The value 
of BRCA1 and BRCA2 germ line mutations and the risk of 
developing breast and ovarian cancer are well established.45
Expression of BRCA protein in ES-NSCLC was 
assessed by IHC in 98 tumor samples. Among 50 cases of 
ES-NSCLC, 50% samples showed low levels of BRCA1 and 
BRCA2 protein.46 Marsit et al. described the methylation sta-
tus of BRCA genes and its relationship to prognosis in 158 
ES-NSCLC patients. Only 3.8% of the tumors were methyl-
ated (only ADC and large-cell carcinomas). No methylation 
in BRCA2 was detected and the methylation of BRCA1 was 
associated with worse OS (HR 3.1; 95% CI, 1.2–7.9).47 Rosell 
et al. examined nine genes involved in the nucleotide excision 
repair pathway, including BRCA1 in 126 ES-NSCLC patients, 
none of whom had received adjuvant chemotherapy. Among 
the genes studied, only high BRCA1 mRNA expression corre-
lated significantly with worse OS (HR, 1.98; p = 0.02).48 In the 
adjuvant setting, the predictive value of BRCA1 was studied 
in 83 patients with ES-NSCLC (stage II–IIIA) and the treat-
ment was tailored according to BRCA1 mRNA levels. With a 
median follow-up of 41.6 months, the median time to progres-
sion for the all patients was 22.9 months. Based on BRCA1 
levels, the median time to progression was 20.3, 56.5, and 
51.9 months for the low, intermediate, and high level groups 
respectively (p = 0.31) and the differences were not statisti-
cally significant.49 Despite its promise as a potential predictive 
biomarker of platinum efficacy, there is a lack of evidence to 
define BRCA as a clinically relevant biomarker in ES-NSCLC.
Table 1 summarizes the biomarkers evaluated in 
ES-NSCLC.
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IMMUNE SYSTEM AND ES-NSCLC
Immunotherapeutic approaches are beginning to play an 
increasingly important role in the treatment of solid tumors. 
There have been important advances in this field leading to the 
approval of ipilimumab in melanoma,50 sipuleucel-T vaccine 
in prostate cancer,51 and reports of clinical activity of mono-
clonal antibodies (mAbs) against programmed cell death-1 
(PD-1) and its ligand (PDL-1) in solid tumors.52
Past trials of immunotherapy in lung cancer have dem-
onstrated a limited activity. Immune mechanisms proposed 
to explain the lack of success in lung cancer include under-
expression of the classic major histocompatibility complex mol-
ecules, overexpression of soluble factors such as prostaglandin 
E2 (PGE2) and transforming growth factor beta (TGF-β) and 
overexpression of specific enzymes such as COX-2 and Ido-1+, 
which help in circumventing successful immune control.53 More 
recently, checkpoint inhibition with anti-PD1 and anti-PDL1 
therapies has yielded remarkable results in heavily pretreated 
patients with NSCLC and provided an impetus to further explore 
the role of immunotherapy in the treatment of lung cancer.
TUMOR INFILTRATING LYMPHOCYTES AS 
PROGNOSTIC BIOMARKERS
Previous studies have demonstrated the prognostic sig-
nificance of tumor infiltrating immune cells and the location 
and density of these infiltrates in ES-NSCLC.54 In a retrospec-
tive study of 1290 patients with lung cancer a correlation was 
shown between tumor infiltrating lymphocytes (TILs), and 
prognosis in a subgroup of patients with stage I SCC. Presence 
of TILs was associated with a significant survival advantage 
over tumors without TILs (p = 0.03).55
Among studies that evaluated specific T-cell subsets 
and their localization in ES-NSCLC, Wakabayashi et al.56 
studied 178 ES-NSCLC and showed that the location of 
CD8 (+) T cells (nests compared with stromal areas) had an 
effect on the prognosis. The actuarial 5-year OS was 47% ver-
sus 60% (p = 0.04). Similarly, the proportion of TILs (CD4 
(+),CD8(+),CD20(+)) in areas enriched for tumor epithe-
lial cells compared with tumor stroma was examined in 335 
cases of ES-NSCLC. It was observed that the presence of 
larger numbers of stromal CD4(+) and CD8(+) T-cells was 
an independent prognostic factor for longer disease-specific 
survival compared with epithelial infiltration with HRs of 2.6 
(p < 0.001) and 1.98 (p < 0.043), respectively.57 These obser-
vations merit further study to determine the significance of 
T-cell infiltration of the stroma.
Regulatory T cells (Tregs or Foxp3-positive T cells) are 
a specific subset of the T cell repertoire which have been dem-
onstrated to be involved in decreasing the antitumor response.58 
It has been shown that recurrence-free survival (RFS) of the 
patients with tumors containing 3 or greater Tregs in 10 high-
power fields was significantly worse than that of patients with 
tumors containing < 3 Tregs/high-power field, especially in 
stage I and II disease (HR, 5.38; p < 0.016).59 A recent study has 
shown the prognostic significance of the ratio of Tregs to CD3 
compared with Tregs alone in 956 cases of stage I NSCLC. A 
low Tregs to CD3 ratio was found to be associated with a longer 
RFS (5-year RFS: 85% versus 77%; p = 0.004).60 Of note, the 
better-than-expected 5-year survival observed in both the groups 
is probably a result of the selection bias since a large fraction of 
the patients enrolled on this study had favorable prognostic fac-
tors including the absence of lymphatic and vascular invasion.
CHECKPOINT MOLECULES AS PROGNOSTIC 
AND PREDICTIVE IMMUNE BIOMARKERS
A relatively new area of research in cancer treatment 
focuses on the role of regulatory signals through molecules 
like cytotoxic T-lymphocyte antigen 4 (CTLA-4) and PDL-1. 
CTLA-4 is a well-known inhibitory molecule of T cell activa-
tion expressed on Tregs. Its expression occurs in the context 
of the interaction between T-cell receptors and antigen pre-
sentation. The expression of CTLA-4 on Tregs can provide 
an explanation for the prognostic significance of Tregs infil-
tration in ES-NSCLC as previously described.59,61 CTLA-4 
overexpression has been found to be more common in ADC 
compared with SCC and appears to be an independent favor-
able prognostic factor (5-year OS of patients with CTLA-4-
overexpressing tumors: 64.8% versus 45.9%; p = 0.078).62
PD-1 is a checkpoint receptor that has immunosup-
pressive functions similar to CTLA-4.63 However a few key 
TABLE 1.  Summary of Biomarkers Evaluated in ES-NSCLC
Gene Protein Function Author and Year Method Number of Patients Comments
TP53 Involved in growth arrest and 
apoptosis
*Mitsudomi15, 2000 IHC 2579 Prognostic for survival
Gene sequencing 650
KRAS Transduction protein with GTPase 
activity
*Shepherd23, 2013 PCR 1543 Not of significant prognostic or 
predictive value
EGFR Tyrosine kinase cell surface receptor Liu28, 2014 PCR 131 Not significantly prognostic
ERBB2 Tyrosine kinase cell surface receptor Xia35, 2012 IHC 172 Prognostic for survival
ERCC1 Enzyme involved in DNA damage 
repair
Friboulet41, 2013 IHC 589 Not predictive for response to 
chemotherapy
RRM1 Enzyme essential for the production 
of deoxyribonucleotides
Zheng40, 2007 AQUA 187 Prognostic for survival
BRCA Participate in the repair of DSB Rosell48, 2007 PCR 126 Prognostic for survival
PCR, polymerase chain reaction; IHC, immunohistochemistry; AQUA, absolute quantification; DSB, double strand break; ES-NSCLC, early-stage non–small-cell lung cancer.
*represents meta-analysis.
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differences between these immune checkpoints include the 
following: (1) PD-1 is activated during the effector stages of 
T-cell activation, (2) the interaction of PD-1 with its ligand 
PD-L1 occurs primarily in peripheral tissues instead of lymph 
nodes, and (3) PD-1 is expressed in tumor tissue as well as 
hematopoietic cells.64 A phase I study by Topalian et al. found 
that 50% of the lung tumors with PD-1 expression (defined 
as ≥5% expression) responded to anti-PD-1 mAb compared 
with 0% of PD-1 negative tumors.52 While the study included 
patients with advanced disease, these results are encouraging 
and potentially applicable to ES-NSCLC in the future.65 It 
should be noted, however that although associations have been 
demonstrated between expression of and response to mAbs 
targeting PD-1 and PD-L1, recent observations also show that 
the expression of PD-1 and PD-L1 is not a prerequisite for 
the generation of a therapeutic response.66,67 This important 
point needs to be borne in mind as studies are designed in the 
future incorporating anti-PD-1/PD-L1 therapies for patients 
with ES-NSCLC.
Studies performed thus far to evaluate the prognostic 
value of PDL-1 expression in ES-NSCLC have generated 
discordant results. In one of the largest validation studies 
for PD-L1 expression (any level of expression in tumor cells 
above the negative control was considered a positive result), 
velcheti et al., demonstrated PD-L1 protein expression in 
two separate cohorts (enrolled in two different countries) of 
NSCLC that included 88% and 84% cases with stage I to 
III disease respectively. Expression of PDL-1was detected in 
36% and 25% cases in the two cohorts and was associated 
with better OS independent of others factors including histol-
ogy in each of the cohorts (p = 0.036 and 0.027).68 Of note, 
this study did not analyze the effects of treatment adminis-
tered. Therefore, although it provides valuable hypothesis-
generating data, this study precludes the classification of 
PD-L1 expression as an established prognostic factor in 
ES-NSCLC.
GENE SIGNATURES AS BIOMARKERS
A gene signature is a biomarker in which the expres-
sion of multiple genes, proteins, or microRNA (miRNA) is 
measured and combined into a group with possibly superior 
prognostic or predictive potential as compared with its individ-
ual components. Data from gene signatures may be presented 
in the form of risk scores as is the case with the Oncotype DX 
assay.69 Signatures may also be presented as categorical sub-
groups such as activated B-cell-like or germinal center B-cell 
like diffuse large B-cell lymphoma.70
In ES-NSCLC, several studies have attempted to iden-
tify gene expression signatures with prognostic or predic-
tive potential by using diverse platforms and genes. Details 
of some gene signatures evaluated in ES-NSCLC are pre-
sented in Table 2 to illustrate the diversity of genes chosen, 
types of platforms, and the primary goals used to capture 
prognostic and/or predictive information. One of the chal-
lenges in developing gene signatures is to make them simple 
and reproducible. Chen et al. identified a prognostic reverse-
transcriptase (RT)-PCR-based five-gene signature (including 
DUSP6, MMD, STAT1, ERBB3, and LCK) using risk scores 
based on microarray analyses of 125 ES-NSCLC tumor speci-
mens. A high-risk score was associated with increased risk 
of death (HR for death 1.92, p = 0.03).71 Lau et al. developed 
another RT-PCR-based signature utilizing a three gene clus-
ter (STX1A, HIF1A, and CCR7) with prognostic significance. 
Based on analysis of 147 patients, they were able to stratify 
stage I ES-NSCLC into two prognostic groups. When poor 
risk scores were compared to good risk scores, the HR for 
survival was 5.9 (p = 0.0019).72
These and other early studies of gene expression sig-
natures using RT-PCR evaluated only a limited number of 
genes as opposed to larger microarray platforms that have 
tested hundreds of genes with a goal of developing a test that 
could be easily applied in the clinical setting. These studies 
are limited by the heterogeneous stages of the disease in the 
study population, the lack of information on standard clini-
cal predictive factors, and perhaps most importantly, the lack 
of blinded validation in independent cohorts in most cases. A 
review of 16 studies published on gene expression profiling in 
NSCLC from 2002 to 2009 found no evidence of the clinical 
utility of these signatures beyond that obtained from currently 
used clinical parameters.73 More recently, Kratz et al. reported 
a 14-gene prognostic signature using quantitative PCR in 361 
patients with non-squamous ES-NSCLC and validated their 
TABLE 2.  Examples of Studies Evaluating Different Types of Signatures in ES-NSCLC
Signature Characteristics
Independent 
Validation
No. of Patients 
and Stage Author and Year Comments
Immune genes signature  
(meta-analysis)
Different miRNA 
platforms
Yes 1625*
I to III
Suzuki54, 2011 Prognostic for PFS
Angiogenic signature Lung tissue miRNA No 20
I to III
Donnem79, 2012 Prognostic for PFS
DNA methylation signature 450000 CpG sites 
analyzed
Yes 237
Stage I
Sandoval76, 2014 Prognostic for PFS
MicroRNA signature 440 miRNA  Yes 251
I to IIIA
Landi78, 2010 Prognostic for OS
Proteomic signature Mass spectrometry 2630 
signals
Yes 116
I to IIIA
Yanagisawa82, 2007  Prognostic for OS
N, number, total number of patients from different studies.
miRNA, micro RNA; PFS, progression-free survival; OS, overall survival; ES-NSCLC, early-stage non–small-cell lung cancer.
* represents meta-analysis.
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results in a large cohort of stage I nonsquamous NSCLC. In 
the validation cohort, the 5-year OS was 71% in low-risk, 
58% in intermediate-risk, and 49% in high-risk patients 
(p = 0.0003). Multivariate analysis indicated that the 14-gene 
signature provided information which added to that obtained 
from standard staging.74
Attempts have been made to develop prognostic gene 
signatures in ES-NSCLC based on the methylation of DNA 
bases or acetylation of histones. A study was conducted to 
determine the methylation status of seven genes in 51 stage 
I NSCLC patients and 116 matched controls. In multivariate 
analysis methylation of p16 and CDH13 was associated with 
a shorter time to recurrence (odds ratio for early recurrence 
25.25; p = 0.006).75 In a separate study in stage I NSCLC the 
methylation status of tumors was investigated in 237 cases 
and validated in a separate cohort of 143 cases. The analy-
sis revealed a five gene methylation signature (HIST1H4F, 
PCDHGB6, NPBWR1, ALX1, HOXA9) that could identify 
patients at a high risk of recurrence (HR, 3.24; p =0.001).76
In recent years, the prognostic value of miRNAs, which 
are small, noncoding, single stranded RNAs that are involved 
in regulation of gene expression, has been explored in 
ES-NSCLC.77 Raponi et al. profiled global miRNA expression 
of 54 SCC samples and found that high miR-146b expression 
was associated with a median OS of 26 months versus 95 
months, (HR, 2.7; p < 0.0035) in the low miR-146b expres-
sion group. Landi et al.78 studied 165 ADC and 125 SCC using 
a miRNA platform and found that five miRNAs of the let-7 
family strongly differentiated ADC from SCC (p < 0.0001) 
and a group of five miRNA signatures correlated with OS, 
independent of the stage and age (p < 0.017).
A number of studies have also been published using dif-
ferent platforms for gene enrichment. This has been done to 
study clusters in specific pathways, such as immune response 
or angiogenesis.54,79 Donnem et al. used this approach to ana-
lyze a set of 128 miRNA in a cohort of ES-NSCLC patients. 
They found a significant correlation between a signature of 
miRNAs and angiogenic marker fibroblastic growth factor 2 
(FGF2) (r = 0.34; p < 0.001). There was no significant cor-
relation with vascular endothelial growth factor A (VEGF-A) 
and hypoxia-inducible factor (HIF-1α).79 Although miRNAs 
show promise as a prognostic marker, most of the miRNAs 
are nonoverlapping in different studies, most likely due to a 
selection bias and design issues.
Far fewer studies have been published on predictive signa-
tures in lung cancer. Zhu et al. performed a study with a 15-gene 
expression signature in 133 frozen tumor samples in the JBR.10 
adjuvant clinical trial. The signature separated patients without 
adjuvant treatment into two groups, high-risk and low-risk. The 
high-risk group had a mortality HR of 15.02 (p = 0.001) in 
both stage I and II compared to the low-risk group. Among 71 
patients receiving chemotherapy, the high-risk group was found 
to have a mortality HR of 0.33 (p = 0.005) versus a HR of 3.67 
(p = 0.013) in the low-risk group.80 This signature was found to 
be both prognostic for survival of untreated patients and predic-
tive for survival after adjuvant chemotherapy.
To summarize, several studies have described gene-
expression signatures that are associated with the outcome in 
ES-NSCLC. However, most of these studies have one or more 
caveats; nonprospective validation, inability to provide addi-
tional information to that gleaned from standard prognostic 
factors, and the lack of strong data to alter clinical treatment 
decisions. Table 3 illustrates key aspects related to the evalua-
tion of prognostic signatures in ES-NSCLC with an emphasis 
on gene signatures.81
CONCLUSIONS
In the present review we have described several poten-
tial biomarkers that have been evaluated in patients with 
ES-NSCLC (Fig. 1). Significant challenges remain in the 
incorporation of information derived from these biomarkers 
into the management of patients with ES-NSCLC. A clear 
distinction has to be made between prognostic and predictive 
factors especially in relation to the clinical trials designed to 
evaluate potential biomarkers or when a retrospective analysis 
is conducted to evaluate a putative biomarker. Figure 2 envi-
sions a future scenario illustrating the use of biomarkers in 
clinical practice.
Many important issues need to be settled before bio-
marker-derived information and gene signatures can find 
widespread acceptance for patients with ES-NSCLC. One 
important issue is the validity and reproducibility of data. Other 
aspects that are no less important include reliability in trial 
implementation and tissue sampling. Uniformity in obtaining 
and handling biopsy samples is of critical importance. Despite 
TABLE 3.  Key Points in the Evaluation of Biomarker Studies 
in ES-NSCLC
Objectives of the trial Is the objective of the trial to identify 
prognostic markers, predictive markers 
or both?
Type of study Is it a biomarker discovery or validation 
study or both?
Population What subgroup of ES-NSCLC does the 
study include? For example, stage IA 
or stage IB, which histology squamous 
vs. nonsquamous. Other subgroups 
EGFR mutated etc.
Specimen Is adequate technical information 
provided regarding tissue processing 
and storage so that technical bias can 
be minimized in future validation 
studies? Is the study performed on 
easily available samples or on fresh-
frozen specimens?
Assay Is the assay clinically applicable? Is the 
technique widely available? Was it 
performed on blinded clinical data?
validation Is the biomarker validated in an 
independent cohort of patients with 
similar characteristics?
Benefit over standard risk factors Does the biomarker offer significant 
benefit or information over standard 
risk factors?
Was independent statistical validation 
performed?
ES-NSCLC, early stage non–small-cell lung cancer; EGFR, epidermal growth factor 
receptor.
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these challenges, utilizing technological advances in bioinfor-
matics and genomics has the potential to result in the discov-
ery of newer molecular markers that might have prognostic 
and predictive value for patients with ES-NSCLC.
Finally, just as in the case of advanced lung cancer where 
biomarkers have an established role in predicting response 
to specific TKI therapies, a similar paradigm needs to be 
explored in ES-NSCLC to identify patients who could derive 
benefit from neoadjuvant and adjuvant therapy. Immune sys-
tem-related biomarkers have the potential to represent the next 
step forward in the effort to develop prognostic and predictive 
markers for patients with ES-NSCLC.
ACKNOWLEDGMENTS
Supported by Intramural Program, National Cancer 
Institute, National Institutes of Health.
REFERENCES
 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics 
Review, 1975-2011. National Cancer Institute. Bethesda, MD. Available 
at http://seer.cancer.gov/csr/1975_2011/. Accessed April 2014.
 2. Früh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age 
on adjuvant cisplatin-based chemotherapy for completely resected non-
small-cell lung cancer. J Clin Oncol 2008;26:3573–3581.
 3. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or 
without postoperative radiotherapy, in operable non-small-cell lung cancer: 
two meta-analyses of individual patient data. Lancet 2010;375:1267–1277.
 4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics 
Review. Bethesda, MD: National Cancer Institute, 2012.
 5. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortal-
ity with low-dose computed tomographic screening. N Engl J Med 
2011;365:395–409.
 6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant che-
motherapy in patients with completely resected non-small-cell lung can-
cer. N Engl J Med 2004;350:351–360.
 7. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus 
cisplatin versus observation in patients with completely resected stage 
IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International 
Trialist Association [ANITA]): a randomised controlled trial. Lancet 
Oncol 2006;7:719–727.
 8. Pignon JP, Tribodet H, Scagliotti Gv, et al. Lung adjuvant cisplatin evalu-
ation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 
2008;26:3552–3559.
 9. Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end 
points—the challenge of statistical validation. Nat Rev Clin Oncol 
2010;7:309–317.
 10. Group EBCTC: Effects of chemotherapy and hormonal therapy for early 
breast cancer on recurrence and 15-year survival: an overview of the ran-
domised trials. Lancet 2005;365:1687–1717.
 11. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J 
Biomed Biotechnol 2011;2011:583929.
 12. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prog-
nostic factors in CLL: clinical stage, IGvH gene mutational status, and 
loss or mutation of the p53 gene are independent prognostic factors. 
Blood 2002;100:1177–1184.
 13. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 
protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, 
response and prognosis. Br J Cancer 1999;79:1185–1189.
 14. Graziano SL, Gu L, Wang X, et al. Prognostic significance of mucin and 
p53 expression in stage IB non-small cell lung cancer: a laboratory com-
panion study to CALGB 9633. J Thorac Oncol 2010;5:810–817.
 15. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of 
p53 alterations in patients with non-small cell lung cancer: a meta-analy-
sis. Clin Cancer Res 2000;6:4055–4063.
 16. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation 
of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma 
of the lung. N Engl J Med 1987;317:929–935.
 17. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clini-
cal significance of K-ras oncogene activation in adenocarcinoma of the 
human lung. Cancer Res 1988;48:5738–5741.
FIGURE 1.  Potential biomarkers in ES-NSCLC: (A) single 
genes; (B) TILs including macrophages (TAM), T lymphocytes 
CD4(+), CD8(+), and T regulatory cell (Tregs); (C) histology 
subtypes: ADC, SCC, BRC, LCNE, SP, and MPP; (D) signatures 
or group of genes, proteins, methylation patterns, microRNAs 
etc. In the center, prognostic factors used in clinic, staging 
(TNM), PS, and age. TILS, tumor infiltrating lymphocytes; 
ADC, adenocarcinoma; SCC, squamous cell carcinoma; 
BRC, bronchoalveolar carcinoma; LCNE, large cell neuroen-
docrine tumor; MPP, micropapillary; SP, solid predominant; 
ES-NSCLC, early-stage non–small-cell lung cancer; TNM, 
tumor, node, metastasis; PS, performance status.
FIGURE 2.  Potential future scenarios for using biomarkers 
in early stage non–small-cell lung cancer. Besides the stage 
(TNM) and histologic subtype, molecular information from 
single genes (e.g., oncogenic drivers, DNA repair genes) or 
groups of genes (signatures) will help in identifying patients 
who could derive benefit from adjuvant treatment. Immune 
biomarkers (TILs) could provide prognostic or predictive infor-
mation relevant to emerging immune therapies. TILS, tumor 
infiltrating lymphocytes; TNM, tumor, node, metastasis.
1616 Copyright © 2014 by the International Association for the Study of Lung Cancer
Burotto et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014
 18. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene 
in surgically resected non-small cell lung cancer patients. Oncogene 
1993;8:2407–2412.
 19. vega F, Iniesta P, Caldes T, et al. Association of K-ras codon 12 trans-
versions with short survival in non-small cell lung cancer. Int J Oncol 
1996;9:1307–1311.
 20. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation 
as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 
1990;323:561–565.
 21. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a 
prognostic marker in non-small cell lung cancer: a combined analysis of 
881 cases. Carcinogenesis 1999;20:1507–1510.
 22. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and 
does it matter? J Clin Oncol 2013;31:1112–1121.
 23. Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognos-
tic and predictive effects of KRAS mutation status and KRAS mutation 
subtype in early-stage resected non-small-cell lung cancer in four trials of 
adjuvant chemotherapy. J Clin Oncol 2013;31:2173–2181.
 24. Herbst RS, Heymach Jv, Lippman SM. Lung cancer. N Engl J Med 
2008;359:1367–1380.
 25. Rusch v, Klimstra D, venkatraman E, et al. Overexpression of the epi-
dermal growth factor receptor and its ligand transforming growth factor 
alpha is frequent in resectable non-small cell lung cancer but does not 
predict tumor progression. Clin Cancer Res 1997;3:515–522.
 26. Sonobe M, Nakagawa M, Takenaka K, et al. Influence of epidermal 
growth factor receptor (EGFR) gene mutations on the expression of 
EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of 
patients with non-small cell lung cancer. J Surg Oncol 2007;95:63–69.
 27. Sonobe M, Kobayashi M, Ishikawa M, et al. Impact of KRAS and 
EGFR gene mutations on recurrence and survival in patients with sur-
gically resected lung adenocarcinomas. Ann Surg Oncol 2012;19(Suppl 
3):S347–S354.
 28. Liu WS, Zhao LJ, Pang QS, et al. Prognostic value of epidermal growth 
factor receptor mutations in resected lung adenocarcinomas. Med Oncol 
2014;31:771.
 29. D’Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of 
EGFR-mutant resected lung cancers: results of testing of 1118 surgical 
specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 
2012;7:1815–1822.
 30. Heinmöller P, Gross C, Beyser K, et al. HER2 status in non-small cell 
lung cancer: results from patient screening for enrollment to a phase II 
study of herceptin. Clin Cancer Res 2003;9:5238–5243.
 31. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 
kinase mutations in tumours. Nature 2004;431:525–526.
 32. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor 
receptor and HER2-neu mRNA expression in non-small cell lung cancer 
is correlated with survival. Clin Cancer Res 2001;7:1850–1855.
 33. Takenaka M, Hanagiri T, Shinohara S, et al. The prognostic significance 
of HER2 overexpression in non-small cell lung cancer. Anticancer Res 
2011;31:4631–4636.
 34. Korrapati v, Gaffney M, Larsson LG, et al. Effect of HER2/neu expres-
sion on survival in non-small-cell lung cancer. Clin Lung Cancer 
2001;2:216–219.
 35. Xia Q, Zhu Z, Wang J, et al. Expression and association of HER2 with 
prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer. 
Tumour Biol 2012;33:1719–1725.
 36. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors a HER2 
mutation: epidemiologic characteristics and therapeutic perspectives. J 
Clin Oncol 2013;31:1997–2003.
 37. Li L, Elledge SJ, Peterson CA, et al. Specific association between the 
human DNA repair proteins XPA and ERCC1. Proc Natl Acad Sci U S A 
1994;91:5012–5016.
 38. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor 
of survival in resected patients with non-small cell lung cancer. Chest 
2005;127:978–983.
 39. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-
small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N 
Engl J Med 2006;355:983–991.
 40. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and 
ERCC1 in lung cancer. N Engl J Med 2007;356:800–808.
 41. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expres-
sion and DNA repair in non-small-cell lung cancer. N Engl J Med 
2013;368:1101–1110.
 42. Davidson JD, Ma L, Flagella M, et al. An increase in the expression 
of ribonucleotide reductase large subunit 1 is associated with gem-
citabine resistance in non-small cell lung cancer cell lines. Cancer Res 
2004;64:3761–3766.
 43. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic 
parameters for overall and disease-free survival in patients with non-
small-cell lung cancer. J Clin Oncol 2004;22:1878–1885.
 44. Bepler G, Zinner RG, Moon J, et al. A phase 2 cooperative group adjuvant 
trial using a biomarker-based decision algorithm in patients with stage 
I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 
2014;doi: 10.1002/cncr.28714 [Epub ahead of print].
 45. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 
2008;359:2143–2153.
 46. Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the chromo-
somal stability control genes BRCA1, BRCA2, and XRCC5 in non-small 
cell lung cancer. Clin Cancer Res 2007;13:832–838.
 47. Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/
BRCA pathway in lung and oral cancers: implications for treatment and 
survival. Oncogene 2004;23:1000–1004.
 48. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor 
in resected non-small-cell lung cancer. PLoS One 2007;2:e1129.
 49. Sanchez JM, Cobo M, Arrabal R, et al. Pilot SCAT trial: Spanish custom-
ized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression 
levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) 
patients (p). J Clin Oncol 2012;30.
 50. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with 
ipilimumab in patients with metastatic melanoma. N Engl J Med 
2010;363:711–723.
 51. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy 
for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.
 52. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-
PD-L1 antibody in patients with advanced cancer. N Engl J Med 
2012;366:2455–2465.
 53. Jadus MR, Natividad J, Mai A, et al. Lung cancer: a classic example of 
tumor escape and progression while providing opportunities for immuno-
logical intervention. Clin Dev Immunol 2012;2012:160724.
 54. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in 
non-small cell lung cancer. Clin Cancer Res 2011;17:5247–5256.
 55. Ruffini E, Asioli S, Filosso PL, et al. Clinical significance of tumor-
infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 
2009;87:365–371.
 56. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, 
not CD8+ T cells in cancer cell nests, are associated with favorable progno-
sis in human non-small cell lung cancers. Cancer Sci 2003;94:1003–1009.
 57. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial 
and stromal lymphocyte infiltration in non-small cell lung cancer. Clin 
Cancer Res 2008;14:5220–5227.
 58. deLeeuw RJ, Kost SE, Kakal JA, et al. The prognostic value of FoxP3+ 
tumor-infiltrating lymphocytes in cancer: a critical review of the litera-
ture. Clin Cancer Res 2012;18:3022–3029.
 59. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regu-
latory T cells are correlated with cyclooxygenase-2 expression and are 
associated with recurrence in resected non-small cell lung cancer. J 
Thorac Oncol 2010;5:585–590.
 60. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune micro-
environment in stage I lung adenocarcinoma: tumor interleukin-12 recep-
tor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent 
predictors of recurrence. J Clin Oncol 2013;31:490–498.
 61. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory mono-
clonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95–106.
 62. Salvi S, Fontana v, Boccardo S, et al. Evaluation of CTLA-4 expression 
and relevance as a novel prognostic factor in patients with non-small cell 
lung cancer. Cancer Immunol Immunother 2012;61:1463–1472.
 63. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoin-
hibitory receptor by a novel B7 family member leads to negative regula-
tion of lymphocyte activation. J Exp Med 2000;192:1027–1034.
1617Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014 Biomarkers in Early-Stage NSCLC
 64. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new 
immunotherapeutic modalities with durable clinical benefit in melanoma 
patients. Clin Cancer Res 2013;19:5300–5309.
 65. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 
2012;366:2443–2454.
 66. Antonia SJ, Grosso JF, Horak CE, et al. Association of tumor PD-L1 
expression and immune biomarkers with clinical activity in patients 
with non-small cell lung cancer treated with nivolumab (anti-PD-1; 
BMS-936558; ONO-4538). J Thorac Oncol 2013;8(suppl 2):Abstract 
P2.11-035.
 67. Gettinger S, Shepherd F, Antonia SJ, et al. First-line nivolumab (anti-
PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: 
Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin 
Oncol 2014;32:5s.
 68. velcheti v, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 
expression in non-small cell lung cancer. Lab Invest 2014;94:107–116.
 69. Paik S, Shak S, Tang G, et al. A multigene assay to predict recur-
rence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 
2004;351:2817–2826.
 70. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse 
large B-cell lymphoma identified by gene expression profiling. Nature 
2000;403:503–511.
 71. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical out-
come in non-small-cell lung cancer. N Engl J Med 2007;356:11–20.
 72. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for 
early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562–5569.
 73. Subramanian J, Simon R. Gene expression-based prognostic signatures in 
lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102:464–474.
 74. Kratz JR, He J, van Den Eeden SK, et al. A practical molecular assay to pre-
dict survival in resected non-squamous, non-small-cell lung cancer: devel-
opment and international validation studies. Lancet 2012;379:823–832.
 75. Brock Mv, Hooker CM, Ota-Machida E, et al. DNA methylation markers and 
early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118–1128.
 76. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA meth-
ylation signature for stage I non-small-cell lung cancer. J Clin Oncol 
2013;31:4140–4147.
 77. Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: 
microRNA signatures in cancer prognosis. Cancer J 2012;18:268–274.
 78. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differen-
tiates histology and predicts survival of lung cancer. Clin Cancer Res 
2010;16:430–441.
 79. Donnem T, Fenton CG, Lonvik K, et al. MicroRNA signatures in tumor 
tissue related to angiogenesis in non-small cell lung cancer. PLoS One 
2012;7:e29671.
 80. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signa-
ture for adjuvant chemotherapy in resected non-small-cell lung cancer. J 
Clin Oncol 2010;28:4417–4424.
 81. Subramanian J, Simon R. What should physicians look for in evalu-
ating prognostic gene-expression signatures? Nat Rev Clin Oncol 
2010;7:327–334.
 82. Yanagisawa K, Tomida S, Shimada Y, et al. A 25-signal proteomic signa-
ture and outcome for patients with resected non-small-cell lung cancer. J 
Natl Cancer Inst 2007;99:858–867.
